{"id":8239,"date":"2021-08-03T09:12:42","date_gmt":"2021-08-03T12:12:42","guid":{"rendered":"https:\/\/www.fie.undef.edu.ar\/ceptm\/?p=8239"},"modified":"2021-08-03T09:12:42","modified_gmt":"2021-08-03T12:12:42","slug":"israel-esta-a-punto-de-convertirse-en-el-primer-pais-del-mundo-en-probar-la-vacuna-oral-covid-19-desarrollada-por-oramed-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.fie.undef.edu.ar\/ceptm\/?p=8239","title":{"rendered":"Israel est\u00e1 a punto de convertirse en el primer pa\u00eds del mundo en probar la vacuna oral COVID 19\u00a0desarrollada por Oramed Pharmaceuticals"},"content":{"rendered":"<p>Oramed es una compa\u00f1\u00eda farmac\u00e9utica en etapa cl\u00ednica basada en tecnolog\u00eda desarrollada por el Centro M\u00e9dico de la Universidad Hadassah de Jerusal\u00e9n.\u00a0En marzo, anunci\u00f3 una empresa conjunta con Premas Biotech, con sede en India, para desarrollar una nueva vacuna oral.\u00a0Juntos formaron Oravax.\u00a0La vacuna se basa en la tecnolog\u00eda de administraci\u00f3n oral \u201cPOD\u201d de Oramed y en la tecnolog\u00eda de vacunas de Premas.<\/p>\n<hr \/>\n<div>\n<div>\n<p>Israel is about to become the first country in the world to test the oral COVID-19 vaccine developed by Oramed Pharmaceuticals, the company&#8217;s CEO Nadav Kidron told The Jerusalem Post.<\/p>\n<p>Oramed\u2019s subsidiary, Oravax Medical, is gearing up to commence clinical trials of its vaccine at Sourasky Medical Center in Tel Aviv after receiving approval for its study protocol from the hospital\u2019s Institutional Review Board. It is now waiting for approval from the Health Ministry, which is expected within a few weeks.<\/p>\n<p>Oravax already completed GMP manufacturing in Europe of several thousand capsules that would be available for the Israeli trial and eventually in other countries.<\/p>\n<\/div>\n<\/div>\n<div>\n<figure id=\"attachment_8241\" aria-describedby=\"caption-attachment-8241\" style=\"width: 663px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" class=\"size-full wp-image-8241\" src=\"https:\/\/www.fie.undef.edu.ar\/ceptm\/wp-content\/uploads\/2021\/08\/anteojos.jpg\" alt=\"\" width=\"663\" height=\"565\" srcset=\"https:\/\/www.fie.undef.edu.ar\/ceptm\/wp-content\/uploads\/2021\/08\/anteojos.jpg 663w, https:\/\/www.fie.undef.edu.ar\/ceptm\/wp-content\/uploads\/2021\/08\/anteojos-300x256.jpg 300w\" sizes=\"(max-width: 663px) 100vw, 663px\" \/><figcaption id=\"caption-attachment-8241\" class=\"wp-caption-text\">Oramed Pharmaceuticals CEO Nadav Kidron Photograph (Courtesy)<\/figcaption><\/figure>\n<p>Oramed is a clinical-stage pharmaceutical company based on technology developed by Jerusalem\u2019s Hadassah-University Medical Center. In March, it announced a joint venture with India-based Premas Biotech to develop a novel oral vaccine. Together they formed Oravax. The vaccine is based on Oramed\u2019s \u201cPOD\u201d oral delivery technology and Premas\u2019s vaccine technology.<\/p>\n<p>Oramed\u2019s technology can be used to orally administer a number of protein-based therapies, which would otherwise be delivered by injection. Oramed is in the midst of a Phase III clinical trial through the US Food and Drug Administration of an oral insulin capsule for Type 1 and Type 2 diabetes.<\/p>\n<p>Premas has been working on developing a vaccine against the novel coronavirus since March.<\/p>\n<p>The new Oravax vaccine candidate targets three structural proteins of the novel coronavirus, as opposed to the single spike protein targeted by the current Moderna and Pfizer vaccines, Kidron said.<\/p>\n<p>As such, \u201cthis vaccine should be much more resistant to COVID-19 variants,\u201d he said. \u201cEven if the virus gets through one line, there is a second line, and if through the second line, there is a third.\u201d<\/p>\n<p>The vaccine is being tested in preclinical studies against COVID-19 variants, including the Delta one.<\/p>\n<p>The company completed a pilot animal study and found that the vaccine promoted the development of Immunoglobulin G (IgG) antibodies and Immunoglobulin A (IgA). IgA is necessary for longer-term immunity.<\/p>\n<p><iframe loading=\"lazy\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/lQXaylnGXLM\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p>The protocol for the inaugural Phase I\/II trial that the company hopes to move forward with at Sourasky would involve 24 volunteers who have not yet been inoculated with another vaccine. Half of the group would take one capsule, and the other half would take two, Kidron said, adding that there is no placebo group because the goal is to measure the level of antibodies and other immunity indicators.<\/p>\n<p>\u201cThe idea here is that we want to show proof of concept: that it works for people,\u201d he said. \u201cI pray and hope that we will. Imagine that we could give someone an oral vaccine and they are vaccinated. This would be a revolution for the entire world.\u201d<\/p>\n<p>With proof of the concept, \u201cthe whole world opens up,\u201d Kidron said.<\/p>\n<p>\u201cAn oral COVID-19 vaccine would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to take the vaccine themselves at home,\u201d he told the Post. \u201cWhile ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the case that a COVID-19 vaccine may be recommended annually like the standard flu shot.\u201d<\/p>\n<p>The advantages of an oral vaccine go beyond safety and efficacy because oral medications tend to have fewer side effects, Kidron said.<\/p>\n<p>The vaccine can be shipped at refrigerator temperatures and even stored at room temperature, \u201cmaking it logistically easier to get it anywhere around the world,\u201d he added.<\/p>\n<p>Finally, an oral vaccine would not require professional administration.<br \/>\nThe Phase I\/II trial is expected to take around six weeks from the time of recruitment.<\/p>\n<p>If the trial is successful, Kidron said he plans to put the vaccine on an accelerated road to receive emergency-use approval in the countries that need it most, such as those in South America that have not been able to acquire enough vaccines to inoculate their populations.<\/p>\n<p>The company would hold its Phase III trial with a limited number of volunteers and look for first approval in one of these \u201cemerging markets,\u201d Kidron said, and only later seek US <a href=\"https:\/\/www.jpost.com\/international\/fda-no-need-for-third-pfizer-vaccine-shot-673665\" target=\"_blank\" rel=\"noopener\">Food and Drug Administration<\/a> authorization.<\/p>\n<p>\u201cIsrael and the US and some of the other richer countries were the first to get Pfizer and Moderna,\u201d he said. \u201cBut it looks to me like the people behind in the race will take over by being the first ones to get the oral vaccine.\u201d<\/p>\n<\/div>\n<p><strong>Fuente:<\/strong> <a href=\"https:\/\/www.jpost.com\/health-science\/israel-to-become-first-in-world-to-test-oral-covid-19-vaccine-674563\" target=\"_blank\" rel=\"noopener\"><em>https:\/\/www.jpost.com<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oramed es una compa\u00f1\u00eda farmac\u00e9utica en etapa cl\u00ednica basada en tecnolog\u00eda desarrollada por el Centro M\u00e9dico de la Universidad Hadassah de Jerusal\u00e9n.\u00a0En marzo, anunci\u00f3 una&hellip; <\/p>\n","protected":false},"author":1,"featured_media":8240,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[36],"tags":[],"_links":{"self":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/posts\/8239"}],"collection":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8239"}],"version-history":[{"count":1,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/posts\/8239\/revisions"}],"predecessor-version":[{"id":8242,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/posts\/8239\/revisions\/8242"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=\/wp\/v2\/media\/8240"}],"wp:attachment":[{"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fie.undef.edu.ar\/ceptm\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}